Hostname: page-component-5c6d5d7d68-sv6ng Total loading time: 0 Render date: 2024-08-27T14:24:01.517Z Has data issue: false hasContentIssue false

Development and Validation of the Isotretinoin Hesitancy Scale

Published online by Cambridge University Press:  27 August 2024

E. Agaoglu
Affiliation:
1Dermatology
I. G. Yilmaz-Karaman*
Affiliation:
2Psychiatry, Eskişehir Osmangazi University, Eskişehir
C. Yastibas-Kacar
Affiliation:
3Psychology, Adana Alparslan Türkeş Science and Technology University, Adana, Türkiye
H. Kaya-Erdogan
Affiliation:
1Dermatology
T. Mutlu
Affiliation:
1Dermatology
E. Acer
Affiliation:
1Dermatology
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Isotretinoin is an effective treatment for acne vulgaris; however, many patients experience anxiety while deciding to get it. Isotretinoin, indeed, has significant adverse effects. On the other hand, effective treatment of acne vulgaris may reduce dermatological and psychiatric complications.

Objectives

The present study aims to develop and validate the Isotretionin Hesitancy Scale to measure the patients’ drawbacks to the treatment.

Methods

The specialists, including dermatologists and mental health professionals, determined an item pool of 30 items. Before the data collection, all items were checked by the researchers in terms of clarity and acceptability. Thus, the eight items were removed from the questionnaire due to having similar meanings, measuring the facts about treatments that are not the study’s objective, and containing unclear statements. The final version of the questionnaire, which consists of 22 items, was applied to the participants.

Results

One hundred patients with acne vulgaris were recruited. Among the participants, 72% were women, and the mean age was 22.72. Most patients’ acne severity was group 2 (40%) and group 3 (36%). Three items were removed because of having low item-total score correlations. Five items were removed in factor analysis because of low factor loading or cross-loading. Exploratory factor analysis results of the scale are presented in Table 1.Table 1.

Exploratory Factor Analysis Results of the Scale

Factor 1(min-max)Factor 2(min-max)Factor 3(min-max)
Isotretinoin treatment can lead to dryness of lips, nose, and eyes.Isotretinoin treatment may have many side effects.Isotretinoin treatment may cause damage to the liver.Side effects of isotretinoin treatment may affect my daily life.Isotretinoin treatment may cause depression.Isotretinoin treatment may cause elevation of cholesterol level.0.516-0.842
Isotretinoin treatment may cause infertility in men.Isotretinoin treatment may cause infertility in women.Isotretinoin treatment may prevent height gain.In case of pregnancy, isotretinoin treatment may cause congenital defects in the baby.0.425-0.945
I’m afraid of using isotretinoin for a long period.I stop the isotretinoin treatment as soon as possible.I will wait as long as I can before using isotretinoin treatment.I need more reassurance about isotretinoin treatment.0.569-0.890

The Cronbach alpha score of the final form of the scale was found to be .81, the internal consistency of the first factor (hesitancy related to reversible adverse effects) was calculated as .79, the second factor (hesitancy related to irreversible adverse effects) was calculated as .78, and the final factor (isotretinoin-related anxiety) was found to be .72.

Conclusions

The Isotretionin Hesitancy Scale is valid and reliable among patients with acne vulgaris.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.